Bellerophon Therapeutics Inc (NASDAQ:BLPH) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 390,200 shares, a decrease of 11.0% from the December 15th total of 438,300 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average trading volume of 519,500 shares, the short-interest ratio is currently 0.8 days.
A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Bellerophon Therapeutics in a research report on Wednesday, December 18th. Maxim Group reissued a “buy” rating and issued a $2.00 target price on shares of Bellerophon Therapeutics in a research report on Thursday, November 7th. Finally, ValuEngine raised Bellerophon Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 12th.
Bellerophon Therapeutics stock opened at $0.36 on Tuesday. Bellerophon Therapeutics has a twelve month low of $0.31 and a twelve month high of $1.01. The stock’s fifty day simple moving average is $0.38 and its 200-day simple moving average is $0.51. The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $24.05 million, a P/E ratio of -1.06 and a beta of -0.11.
Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Sell-side analysts predict that Bellerophon Therapeutics will post -0.23 earnings per share for the current year.
In other Bellerophon Therapeutics news, major shareholder Associates Iv L. P. Venrock sold 704,595 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $0.50, for a total value of $352,297.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Associates Iv L. P. Venrock sold 333,010 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $0.44, for a total value of $146,524.40. The disclosure for this sale can be found here. Corporate insiders own 57.90% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Bellerophon Therapeutics by 8.9% during the second quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock worth $860,000 after acquiring an additional 116,862 shares during the period. Vanguard Group Inc. increased its position in shares of Bellerophon Therapeutics by 15.9% during the second quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock worth $690,000 after acquiring an additional 158,000 shares during the period. Finally, LPL Financial LLC increased its position in shares of Bellerophon Therapeutics by 22.1% during the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 23,650 shares during the period. 50.55% of the stock is currently owned by institutional investors and hedge funds.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Featured Story: Trade War
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.